Pharmacy Quality Alliance, Alexandria, VA.
National Pharmaceutical Council, Washington, DC.
J Manag Care Spec Pharm. 2021 Dec;27(12):1627-1635. doi: 10.18553/jmcp.2021.27.12.1627.
It is well known that medication accessibility reduces morbidity and mortality and increases health-related quality of life; however, despite efforts to improve health care access, many Americans still face challenges in accessing medications. Several health care access and utilization conceptual frameworks have been created and used for decades to illustrate key relationships and interdependencies between elements of the system. However, none of these frameworks have focused exclusively on medication access and associated factors. Medication access is a complex, multidimensional issue that must consider not only patient-specific challenges, but also health system limitations, among others. A better understanding of medication access, beyond the proxy marker of adherence, is needed to identify opportunities to improve accessibility. To develop a conceptual framework that defines a patient's medication access journey and characterizes barriers frequently encountered while seeking medication access. A multistakeholder roundtable composed of 15 experts from across the health care continuum was convened in 2018 by the Pharmacy Quality Alliance to develop a conceptual framework for medication access. The roundtable participants were convened through in-person and telephonic meetings. To inform their work, 2 literature reviews and an environmental scan were conducted to identify medication access barriers, interventions affecting medication access, and medication access quality measures. The resulting framework included 7 nodes that represent the major access points encountered by patients when attempting to access medications: perceived need, help seeking, encounter, prescribing, prescription adjudication, prescription dispensing, and adherence. Also, 18 barriers were identified. Patient health literacy, cost, insurance, and organizational health literacy were predominant barriers across multiple nodes. The framework that was developed provides a patient-focused, holistic view of medication access, incorporating access nodes and corresponding barriers. It also provides a structure to consider key opportunities for interventions and measurement to address medication access challenges. This study was conducted with grant support from the National Pharmaceutical Council, which served as a collaborator in the study. Westrich is employed by the National Pharmaceutical Council. Nelson is employed by the Pharmacy Quality Alliance, which was contracted to conduct this study. Pickering, Campbell, and Holland were employed by the Pharmacy Quality Alliance at the time of this study. This research was presented as a professional poster at the American Public Health Association Annual Meeting in October 2019, Philadelphia, PA.
众所周知,药物可及性可降低发病率和死亡率,提高与健康相关的生活质量;然而,尽管努力改善医疗保健的可及性,许多美国人在获得药物方面仍然面临挑战。几十年来,已经创建并使用了几个医疗保健可及性和利用概念框架,以说明系统各要素之间的关键关系和相互依存关系。然而,这些框架都没有专门侧重于药物可及性和相关因素。药物可及性是一个复杂的、多维度的问题,不仅必须考虑患者的具体挑战,还必须考虑医疗系统的限制等因素。需要更深入地了解药物可及性,而不仅仅是通过药物依从性这个代理指标,以确定改善可及性的机会。 为了开发一个概念框架,定义患者的药物可及性旅程,并描述在寻求药物可及性时经常遇到的障碍。 2018 年,由药剂质量联盟召集了一个由医疗保健领域的 15 名专家组成的多方利益相关者圆桌会议,以制定一个药物可及性概念框架。圆桌会议参与者是通过面对面和电话会议召集的。为了为他们的工作提供信息,进行了 2 次文献回顾和环境扫描,以确定药物可及性障碍、影响药物可及性的干预措施以及药物可及性质量措施。 由此产生的框架包括 7 个节点,代表患者在尝试获得药物时遇到的主要可及点:感知需求、寻求帮助、相遇、处方、处方裁定、处方配药和依从性。此外,还确定了 18 个障碍。在多个节点中,患者健康素养、成本、保险和组织健康素养是主要障碍。 该框架提供了一个以患者为中心的、全面的药物可及性视图,包含了可及性节点和相应的障碍。它还提供了一个结构,可以考虑解决药物可及性挑战的关键干预措施和测量机会。 这项研究是在国家制药理事会的资助下进行的,该理事会是该研究的合作者。Westrich 受雇于国家制药理事会。Nelson 受雇于药剂质量联盟,该联盟受委托进行这项研究。Pickering、Campbell 和 Holland 在这项研究期间受雇于药剂质量联盟。这项研究作为专业海报在美国公共卫生协会 2019 年 10 月在费城举行的年会上进行了介绍。